We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GE Healthcare's (GEHC) Revolution RT to Aid Cancer Treatment
Read MoreHide Full Article
GE Healthcare (GEHC - Free Report) announced the launch of a new radiation therapy computed tomography (CT) solution, Revolution RT, which will likely create a more streamlined standard of care for cancer patients. The company unveiled the product at the European Society for Therapeutic Radiology and Oncology (ESTRO) 2024 Congress.
Apart from Revolution RT, the company also announced an updated and artificial intelligence (AI)-enhanced version of the Intelligent Radiation Therapy (iRT) platform at the ESTRO Congress. The company will also present the newly acquired MIM Software portfolio that will help it to build advanced AI and Digital solutions for more personalized oncology radiation therapy.
GEHC has been actively building its AI-driven solutions portfolio with the addition of several new services or products so far in 2024. The medical sector or the medical device companies in particular, have shown rapid adoption of AI to build more precise and accurate devices catering to various categories of the healthcare industry. This innovation in AI should help GEHC to boost its market presence in the medical devices market going forward.
Revolution RT
GE Healthcare's Revolution RT is set to enhance CT imaging accuracy in radiation therapy. It features a wide-bore CT platform that offers precision simulation and reduced workflow complexity, with the goal of expedited patient care. The company developed the Revolution RT with advanced capabilities for radiation therapy simulation, diagnostics and interventions. This design aims to cater to a larger number of patients and establish a more efficient standard of care.
The Revolution RT incorporates precision radiotherapy simulation to enhance imaging accuracy, and improve workflow and efficiency. It also utilizes deep learning technology for accurate patient imaging.
iRT Platform Upgrade
The updated platform enables greater interoperability, connectivity and efficiency throughout the entirety of the radiation oncology care continuum. It also includes an integrated workflow that connects various applications to an intuitive single interface. Apart from these, it also offers multi-vendor interoperability, seamless data transfer and task automation, and a catalog of RT applications.
This AI-enhanced platform now interfaces with the Spectronic magnetic resonance imaging (MRI) Planner. It will use AI to convert MR simulation images into an equivalent CT image that can be used for RT dose calculation.
The iRT platform will also offer a novel approach to treatment plan creation while the patient is still on the simulation table. This can potentially reduce the time between simulation and the first radiation dose. The new version of iRT is also updated to allow user-enabled personalization, analytics and notification modules.
GE Healthcare and the Radiological Society of North America announced their partnership to offer mammography equipment, training and educational materials to the radiologists at Muhimbili National Hospital, part of the Muhimbili University of Health and Sciences, Tanzania, last month. The deal is likely to increase screening availability and assist medical professionals in reducing the nation's breast cancer death rate.
In April, GEHC announced its latest breast cancer detection technology during the Society of Breast Imaging Symposium in Montreal, Canada. The showcase featured the Mobile Mammography Screening Truck, the recently released MyBreastAI Suite and Pristina Bright to demonstrate the company’s personalized approach to transforming breast cancer imaging.
The company announced the launch of the Prostate Volume Assist (PVA) urology-based AI software feature in March.
Zacks Rank and Stocks to Consider
GE Healthcare currently carries a Zacks Rank #3 (Hold)
Some better-ranked stocks in the broader medical space that have announced quarterly results are Align Technology, Inc. (ALGN - Free Report) , Ecolab (ECL - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Revenues of $997.4 million outpaced the consensus mark by 2.6%.
Align Technology has a long-term estimated growth rate of 6.9%. Its earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 5.9%.
Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 1.7%.
Ecolab’s shares have risen 33.8% against the industry’s 9.3% decline in the past year.
Boston Scientific reported first-quarter 2024 adjusted EPS of 56 cents, which beat the Zacks Consensus Estimate by 9.8%. Revenues of $3.86 billion surpassed the Zacks Consensus Estimate by 4.9%. The company currently carries a Zacks Rank #2.
Boston Scientific has a long-term estimated growth rate of 12.5%. BSX’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.5%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GE Healthcare's (GEHC) Revolution RT to Aid Cancer Treatment
GE Healthcare (GEHC - Free Report) announced the launch of a new radiation therapy computed tomography (CT) solution, Revolution RT, which will likely create a more streamlined standard of care for cancer patients. The company unveiled the product at the European Society for Therapeutic Radiology and Oncology (ESTRO) 2024 Congress.
Apart from Revolution RT, the company also announced an updated and artificial intelligence (AI)-enhanced version of the Intelligent Radiation Therapy (iRT) platform at the ESTRO Congress. The company will also present the newly acquired MIM Software portfolio that will help it to build advanced AI and Digital solutions for more personalized oncology radiation therapy.
GEHC has been actively building its AI-driven solutions portfolio with the addition of several new services or products so far in 2024. The medical sector or the medical device companies in particular, have shown rapid adoption of AI to build more precise and accurate devices catering to various categories of the healthcare industry. This innovation in AI should help GEHC to boost its market presence in the medical devices market going forward.
Revolution RT
GE Healthcare's Revolution RT is set to enhance CT imaging accuracy in radiation therapy. It features a wide-bore CT platform that offers precision simulation and reduced workflow complexity, with the goal of expedited patient care. The company developed the Revolution RT with advanced capabilities for radiation therapy simulation, diagnostics and interventions. This design aims to cater to a larger number of patients and establish a more efficient standard of care.
The Revolution RT incorporates precision radiotherapy simulation to enhance imaging accuracy, and improve workflow and efficiency. It also utilizes deep learning technology for accurate patient imaging.
iRT Platform Upgrade
The updated platform enables greater interoperability, connectivity and efficiency throughout the entirety of the radiation oncology care continuum. It also includes an integrated workflow that connects various applications to an intuitive single interface. Apart from these, it also offers multi-vendor interoperability, seamless data transfer and task automation, and a catalog of RT applications.
This AI-enhanced platform now interfaces with the Spectronic magnetic resonance imaging (MRI) Planner. It will use AI to convert MR simulation images into an equivalent CT image that can be used for RT dose calculation.
The iRT platform will also offer a novel approach to treatment plan creation while the patient is still on the simulation table. This can potentially reduce the time between simulation and the first radiation dose. The new version of iRT is also updated to allow user-enabled personalization, analytics and notification modules.
GE HealthCare Technologies Inc. Price
GE HealthCare Technologies Inc. price | GE HealthCare Technologies Inc. Quote
Notable Developments
GE Healthcare and the Radiological Society of North America announced their partnership to offer mammography equipment, training and educational materials to the radiologists at Muhimbili National Hospital, part of the Muhimbili University of Health and Sciences, Tanzania, last month. The deal is likely to increase screening availability and assist medical professionals in reducing the nation's breast cancer death rate.
In April, GEHC announced its latest breast cancer detection technology during the Society of Breast Imaging Symposium in Montreal, Canada. The showcase featured the Mobile Mammography Screening Truck, the recently released MyBreastAI Suite and Pristina Bright to demonstrate the company’s personalized approach to transforming breast cancer imaging.
The company announced the launch of the Prostate Volume Assist (PVA) urology-based AI software feature in March.
Zacks Rank and Stocks to Consider
GE Healthcare currently carries a Zacks Rank #3 (Hold)
Some better-ranked stocks in the broader medical space that have announced quarterly results are Align Technology, Inc. (ALGN - Free Report) , Ecolab (ECL - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Align Technology, carrying a Zacks Rank of 2 (Buy) at present, reported first-quarter 2024 adjusted earnings per share (EPS) of $2.14, which beat the Zacks Consensus Estimate by 8.1%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Revenues of $997.4 million outpaced the consensus mark by 2.6%.
Align Technology has a long-term estimated growth rate of 6.9%. Its earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 5.9%.
Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 1.7%.
Ecolab’s shares have risen 33.8% against the industry’s 9.3% decline in the past year.
Boston Scientific reported first-quarter 2024 adjusted EPS of 56 cents, which beat the Zacks Consensus Estimate by 9.8%. Revenues of $3.86 billion surpassed the Zacks Consensus Estimate by 4.9%. The company currently carries a Zacks Rank #2.
Boston Scientific has a long-term estimated growth rate of 12.5%. BSX’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.5%.